Quantcast

Latest Aprepitant Stories

2014-02-11 20:21:26

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/tgtpbg/drug_solubility) has announced the addition of the "Concise Analysis of Drug Solubility Technology: Spray Drying, Extrusion, and SCF" [http://www.researchandmarkets.com/research/tgtpbg/drug_solubility ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) As drug suppliers re-examine their business models to adjust...

2014-01-29 16:29:05

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bgdzzw/tesaros) has announced the addition of the "Tesaro's Rolapitant: Competition for Emend" [http://www.researchandmarkets.com/research/bgdzzw/tesaros ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Tesaro's rolapitant is a NK-1 inhibitor in phase III trials for the prophylaxis of chemotherapy-induced nausea and...

2011-06-08 05:00:00

LONDON, June 8, 2011 /PRNewswire/ -- - New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods The combination of palonosetron (0.25 mg iv every 48...

2010-10-13 07:00:00

NEW YORK and WHITEHOUSE STATION, N.J., Oct. 13 /PRNewswire-FirstCall/ -- Weight Watchers International, Inc., the world's leading provider of weight management services, and Merck, a global healthcare leader, announced today an innovative collaboration focused on fighting obesity. The two companies will launch an initiative in which Merck will provide physicians and other health care providers with educational information about the Weight Watchers® program and its...

2010-09-07 08:53:00

RYE, N.Y., Sept. 7 /PRNewswire/ -- Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the position of Director of New Product Development. In his new position, Szigethy will have direct oversight of improving existing products and directing the development of new products. As Curemark continues to anticipate expansion of its clinical trials...

2010-07-02 16:23:00

WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication. The FDA...

2010-06-11 09:09:00

Nausea and Vomiting Present Obstacles to Patients' Life-Saving Chemotherapy Maintenance; CareLine Program Provides Direct Assistance to Patients Experiencing Side Effects of Chemotherapy, Seeking Access to Anti-Nausea Care WASHINGTON, June 11 /PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) - a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.